Aspirin-exacerbated respiratory disease (AERD) is optimally managed by endoscopic sinus surgery (ESS) followed by aspirin therapy after desensitization (ATAD). Most AERD quality of life (QOL) studies use the 22-item Sinonasal Outcomes Test (SNOT-22), which focuses predominantly on sinonasal outcomes.
Objective
This study seeks to assess QOL outcomes in AERD patients after ESS and ATAD via the 12-item Short Form Survey (SF-12), a well-validated QOL measure for general health status of chronic conditions.
Methods
Retrospective review of 112 AERD patients who underwent ESS followed by ATAD at our institution between 2016 and 2019. SF-12 was collected preoperatively, postoperatively/pre-AD, and serially post-AD (1–3, 4–6, 7–12, and >12 months). Optum® PRO CoRE software was used to compare data to national norms. ANOVA was performed comparing physical component summary (PCS), mental component summary (MCS) and eight health domains (physical functioning, role physical, general health, bodily pain, vitality, social functioning, role emotional, and mental health).
Results
AERD patients showed improvement in PCS scores across all timepoints after ESS and ATAD (p = 0.004). When stratified by gender, women demonstrated an improvement in PCS scores (p = 0.004). Within the domains, there were significant improvements in social functioning (SF), role physical (RP), and bodily pain (BP) at all timepoints (SF: p = 0.006; RP: p = 0.005; BP: p < 0.001).
Conclusions
AERD patients undergoing ESS and ATAD show improvement in physical QOL and 3 of the 8 health domains as measured by the SF-12. Future studies can use the SF-12 to study the impact of AERD treatment versus other chronic diseases and health demographics.
SzczeklikANizankowskaEDuplagaM.Natural history of aspirin-induced asthma. AIANE Investigators. European network on aspirin-induced asthma. Eur Respir J. 2000;
16(3):432–436.
2.
Berges-GimenoMPSimonRAStevensonDD.The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2002;
89(5):474–478.
3.
ChoKSSoudryEPsaltisAJ, et al.
Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease. Otolaryngol Head Neck Surg. 2014;
151(4):575–581.
4.
AdappaNDRanasingheVJTropeMBrooksSG, et al.
Outcomes after complete endoscopic sinus surgery and aspirin desensitization in aspirin-exacerbated respiratory disease. Int Forum Allergy Rhinol. 2018;
8(1):49–53.
5.
Berges-GimenoMPSimonRAStevensonDD.Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003;
111(1):180–186.
6.
TajudeenBASchwartzJSBossoJV.The role of aspirin desensitization in the management of aspirin-exacerbated respiratory disease. Curr Opin Otolaryngol Head Neck Surg. 2017;
25(1):30–34.
7.
ChuDKLeeDJLeeKM, Schünemann HJ, Szczeklik W, Lee JM.
Benefits and harms of aspirin desensitization for aspirin-exacerbated respiratory disease: a systematic review and meta-analysis. Int Forum Allergy Rhinol. 2019;
9(12):1409–1419.
8.
WaldramJWaltersKSimonR, Woessner K, Waalen J, White A.
Safety and outcomes of aspirin desensitization for aspirin-exacerbated respiratory disease: a single-center study. J Allergy Clin Immunol. 2018;
141(1):250–256.
9.
HorsmanJFurlongWFeenyD, Torrance G.
The health utilities index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;
1:54.
10.
McHorneyCAWareJEJrLuJF, Sherbourne CD.
The MOS 36-item Short-Form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;
32(1):40–66.
11.
WareJJrKosinskiMKellerSD.A 12-item Short-Form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;
34(3):220–233.
12.
BewickJMorrisSHopkinsC, Erskine S, Philpott CM.
Health utility reporting in chronic rhinosinusitis patients. Clin Otolaryngol. 2018;
43(1):90–95.
13.
GliklichRMetsonR.Of sinus surgery on quality of life. Otolaryngol–Head Neck Surg. 1997;
117(1):12–17.
14.
KhanAHuynhTMTVandeplasG, et al.
The GALEN rhinosinusitis cohort: chronic rhinosinusitis with nasal polyps affects health-related quality of life. Rhinology. 2019;
57(5):343–351.
15.
MetsonRBGliklichRE.Clinical outcomes in patients with chronic sinusitis. Laryngoscope. 2000;
110(S94):24–28.
16.
BhattacharyyaNVilleneuveSJoishVN, et al.
Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. Laryngoscope. 2019;
129(9):1969–1975.
17.
CaulleyLThavornKRudmikL, Cameron C, Kilty S.
Direct costs of adult chronic rhinosinusitis by using 4 methods of estimation: results of the US medical expenditure panel survey. J Allergy Clin Immunol. 2015;
136(6):1517–1522.
18.
RudmikL.Economics of chronic rhinosinusitis. Curr Allergy Asthma Rep. 2017;
17(4):20.
19.
BenningerMSHolyCE.The impact of endoscopic sinus surgery on health care use in patients with respiratory comorbidities. Otolaryngol Head Neck Surg. 2014;
151(3):508–515.
20.
WorkmanADBleierBS.Biologic therapies versus surgical management for aspirin-exacerbated respiratory disease: a review of preliminary data, efficacy, and cost. World J Otorhinolaryngol Head Neck Surg. 2020;
6(4):230–234.
21.
KosinskiMWareJETurner-BowkerDM, Gandek B. User's Manual for the SF-12v2 Health Survey: With a Supplement Documenting the SF-12Æ Health Survey.
Lincoln, RI:
QualityMetric Incorporated; 2007.
22.
GliklichREMetsonR.The health impact of chronic sinusitis in patients seeking otolaryngologic care. Otolaryngol Head Neck Surg. 1995;
113(1):104–109.
23.
ChesterACSindwaniRSmithTL, Bhattacharyya N.
Systematic review of change in bodily pain after sinus surgery. Otolaryngol Head Neck Surg. 2008;
139(6):759–765.
24.
McMainsKCKountakisSE.Medical and surgical considerations in patients with Samter’s triad. Am J Rhinol. 2006;
20(6):573–576.
25.
BossoJVLockeTBKuanEC, et al.
Complete endoscopic sinus surgery followed by aspirin desensitization is associated with decreased overall corticosteroid use. Int Forum Allergy Rhinol. 2020;
10(9):1043–1048.
26.
ShahSJAbuzeidWMPonduriA, et al.
Endoscopic sinus surgery improves aspirin treatment response in aspirin-exacerbated respiratory disease patients. Int Forum Allergy Rhinol. 2019;
9(12):1401–1408.
27.
HavelMErtlLBraunschweigF, et al.
Sinonasal outcome under aspirin desensitization following functional endoscopic sinus surgery in patients with aspirin triad. Eur Arch Otorhinolaryngol. 2013;
270(2):571–578.
28.
SommerDDRotenbergBWSowerbyLJ, et al.
A novel treatment adjunct for aspirin exacerbated respiratory disease: the low-salicylate diet: a multicenter randomized control crossover trial. Int Forum Allergy Rhinol. 2016;
6(4):385–391.
29.
EsmaeilzadehHNabaviMAryanZ, et al.
Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: a randomized double-blind placebo-controlled trial. Clin Immunol (Orlando, FL). 2015;
160(2):349–357.
30.
RowanNRSolerZMStorckKA, et al.
Impaired eating-related quality of life in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2019;
9(3):240–247.
31.
FeldmanJMZeiglerAENelsonK, et al.
Depression symptoms and quality of life among individuals with aspirin-exacerbated respiratory disease. J Asthma. 2019;
56(7):731–738.
32.
GudziolVMichelMSonnefeldC, Koschel D, Hummel T.
Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study. Eur Arch Otorhinolaryngol. 2017;
274(3):1487–1493.
33.
ErdoganTKarakayaGKalyoncuAF.Comorbid diseases in aspirin-exacerbated respiratory disease, and asthma. Allergologia et Immunopathologia. 2015;
43(5):442–448.
34.
LaborMLaborSJurićI, Fijačko V, Grle SP, Plavec D.
Mood disorders in adult asthma phenotypes.J Asthma. 2018;
55(1):57–65.
35.
BhattacharyyaNOrlandiRRGrebnerJ, Martinson M.
Cost burden of chronic rhinosinusitis: a claims-based study. Otolaryngol Head Neck Surg. 2011;
144(3):440–445.
36.
BhattacharyyaN.Incremental health care utilization and expenditures for chronic rhinosinusitis in the United States. Ann Otol Rhinol Laryngol. 2011;
120(7):423–427.
37.
RudmikLSolerZMMaceJC, Schlosser RJ, Smith TL.
Economic evaluation of endoscopic sinus surgery versus continued medical therapy for refractory chronic rhinosinusitis. Laryngoscope. 2015;
125(1):25–32.
38.
ShakerMLobbAJenkinsP, et al.
An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2008;
121(1):81–87.
DeCondeASBodnerTEMaceJC, Smith TL.
Response shift in quality of life after endoscopic sinus surgery for chronic rhinosinusitis. JAMA Otolaryngol Head Neck Surg. 2014;
140(8):712–719.
41.
BenningerMSSeniorBA.The development of the rhinosinusitis disability index. Arch Otolaryngol Head Neck Surg. 1997;
123(11):1175–1179.
42.
Quintanilla-DieckLLitvackJRMaceJC, Smith TL.
Comparison of disease-specific quality-of-life instruments in the assessment of chronic rhinosinusitis. Int Forum Allergy Rhinol. 2012;
2(6):437–443.
43.
BrazierJEHarperRJonesNM, et al.
Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;
305(6846):160–164.
